Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma:A Systematic Evaluation / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1887-1893, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-781523
ABSTRACT
OBJECTIVE@#To evaluate the efficacy and safety of carfilzomib in the treatment of multiple myeloma (MM).@*METHODS@#Computer was used to search PubMed, EMbase, Cochrane library and MEDLINE databases for carfilzomib treatment of MM. Clinical features and results were extracted and meta-analysis was performed using Stata12.0 software.@*RESULTS@#Twelve eligible Phase I/II, II and III clinical trials of carfilzomib were extracted and 2 487 MM patients involved in evaluable. The summary analysis showed that the rate of complete response (CR) of carfilzomib treatment was 28%, the rate of ≥very good partial response (VGPR) was 73%, and the rate of overall response rate (0RR) was 93%; the 1-year progression-free survival (PFS) rate of MM patients was 93%, the 2-year PFS rate was 85%, and the 3-year PFS rate was 74%. Three randomized controlled trials showed a significant improvement in ORR [OR=1.644, 95% CI=(1.056, 2.560) ] (P<0.05) and clinical benefit rate (CBR) in MM patients [OR=1.595, 95%) CI=(1.044, 2.435) ] (P<0.05). Compared with the control group, the OR of cardiotoxicity (P<0.05) was significantly increased, while that of peripheral neuropathy (P>0.05) was not significantly changed.@*CONCLUSION@#Compared with traditional treatments, carfilzomib significantly improves survival in the patients with multiple myeloma without increasing the incidence of peripheral neuropathy, but the incidence of cardiotoxicity seems higher.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oligopeptides
/
Remission Induction
/
Antineoplastic Combined Chemotherapy Protocols
/
Therapeutic Uses
/
Drug Therapy
/
Multiple Myeloma
Type of study:
Controlled clinical trial
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS